Syndax Pharmaceuticals

Yahoo Finance • 20 days ago

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts – – Retrospective review sh... Full story

Yahoo Finance • 25 days ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted induceme... Full story

Yahoo Finance • 27 days ago

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will... Full story

Yahoo Finance • 30 days ago

Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)  is one of the most promising stocks with huge upside potential. On November 24, Barclays raised the firm’s price target on Syndax to $35 from $22, while maintaining an Overweight rating on the sha... Full story

Yahoo Finance • 2 months ago

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia... Full story

Yahoo Finance • 2 months ago

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event... Full story

Yahoo Finance • 2 months ago

Syndax Pharmaceuticals Q3 2025 Earnings Preview

* Syndax Pharmaceuticals (SNDX [https://seekingalpha.com/symbol/SNDX]) is scheduled to announce Q3 earnings results on Monday, November 3rd, after market close. The consensus EPS Estimate is -$0.71 [https://seekingalpha.com/symbol/SNDX/e... Full story

Yahoo Finance • 2 months ago

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial r... Full story

Yahoo Finance • 2 months ago

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved indication for Revuforj in less than one year further solidifies Sy... Full story

Yahoo Finance • 2 months ago

Syndax gains additional indication for Revuforj in acute myeloid leukemia

[Fda Approved Stamp] atakan * The US FDA has approved Syndax Pharmaceuticals' (NASDAQ:SNDX [https://seekingalpha.com/symbol/SNDX]) Revuforj (revumenib) for relapsed or refractory acute myeloid leukemia in patients with a certain genetic... Full story

Yahoo Finance • 3 months ago

Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20. On September 19, Syndax Pharmaceuticals announced a major milestone: the National Comprehensive Cancer Network/NCCN updated its Clinical Practice Guideli... Full story

Yahoo Finance • 3 months ago

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN... Full story

Yahoo Finance • 4 months ago

Syndax Announces Participation in September Investor Conferences

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as w... Full story

Yahoo Finance • 5 months ago

Citi ups Syndax target, opens ‘upside catalyst watch’

Citi analyst Yigal Nochomovitz raised the firm’s price target on Syndax (SNDX) to $51 from $46 and keeps a Buy rating on the shares. The firm also added a positive “upside catalyst watch” on Syndax ahead of the PDUFA deadline in relapsed o... Full story

Yahoo Finance • 5 months ago

Stocks making the biggest moves midday: Pfizer, Palantir, Coinbase, Staar Surgical and more

Check out some of the companies making the biggest moves midday: Staar Surgical — The implantable eye lens maker ripped 45% higher after agreeing to be bought by Alcon for $28 per share in cash, valuing Staar at about $1.5 billion. The dea... Full story

Yahoo Finance • 5 months ago

Stocks making the biggest premarket moves: Pfizer, Eaton, Palantir, Yum and more

Check out the companies making the biggest moves in premarket trading: Palantir Technologies — The defense technology stock jumped 6.8% after quarterly revenue exceeded $1 billion for the first time and it raised full-year guidance. Palant... Full story

Yahoo Finance • 5 months ago

Earnings call transcript: Syndax Pharmaceuticals Q2 2025 beats forecasts, stock rises

Syndax Pharmaceuticals reported its second-quarter 2025 earnings, posting a narrower-than-expected loss per share and exceeding revenue forecasts. The earnings per share (EPS) came in at -$0.83, surpassing the forecast of -$1.01, marking a... Full story

Yahoo Finance • 5 months ago

Syndax Pharmaceuticals earnings beat by $0.18, revenue topped estimates

Investing.com - Syndax Pharmaceuticals (NASDAQ: SNDX) reported second quarter EPS of $-0.83, $0.18 better than the analyst estimate of $-1.01. Revenue for the quarter came in at $37.96M versus the consensus estimate of $27.13M. Syndax P... Full story

Yahoo Finance • 5 months ago

Stocks making the biggest moves after hours: Palantir, Hims & Hers Health, Vertex Pharmaceuticals and more

Check out the companies making headlines in extended trading. Palantir — The defense technology stock advanced 4% after second-quarter earnings exceeded Wall Street's expectations. Palantir said it reported adjusted earnings of 16 cents pe... Full story

Yahoo Finance • 5 months ago

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue... Full story